Targeting Sorafenib-Resistant Hccs: a Novel T Cell Immunotherapeutic Strategy with in Situ Injectable Thermosensitive Peg-Plga- Coated Igf1r/Cd3 Bispecific Antibody and Preclinical 3d Organoid Model (1/3)

本計畫將針對雷沙瓦抗藥性肝細胞癌 (Sorafenib-resistant HCC)，以3D腫瘤類器官為模式，發展一新穎結合可注射熱敏性水膠 PEG-PLGA- coated X 蛋白/CD3 雙功能抗體武裝免疫T細胞療法與免疫檢查點抑制劑（immune checkpoint blockade anti-PDL1 Ab atezolizumab），精準治療雷沙瓦抗藥性肝細胞癌，並進一步提供克服雷沙瓦耐藥性癌症治療的科學依據。